PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSelinexor
Xpovio, Nexpovio(selinexor)
Nexpovio, Xpovio (selinexor) is a small molecule pharmaceutical. Selinexor was first approved as Xpovio on 2019-07-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target exportin-1.
Download report
Favorite
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Xpovio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selinexor
Tradename
Company
Number
Date
Products
XPOVIOKaryopharm TherapeuticsN-212306 RX2019-07-03
6 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
xpovioNew Drug Application2025-09-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
SELINEXOR, XPOVIO, KARYOPHARM THERAPS
2027-12-18ODE*, ODE-346
2027-06-22ODE*, ODE-310
2026-07-03ODE*, ODE-257
2024-07-03NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Selinexor, Xpovio, Karyopharm Theraps
105191392035-08-14DS, DPU-2584, U-2855, U-3018
117461022035-08-14U-2584, U-2855, U-3018
117534012035-08-14DPU-2584, U-2855, U-3018
118076292035-08-14DS, DP
89999962033-07-03DS, DP
90798652032-07-26U-2584, U-2855, U-3018
97142262032-07-26DS, DP
105441082032-07-26U-2584, U-3018
110346602032-07-26U-2584, U-3018
117877712032-07-26U-2584, U-2855, U-3018
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX66: Selinexor
HCPCS
No data
Clinical
Clinical Trials
187 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.07172—122
Plasma cell neoplasmsD054219——6121——15
RecurrenceD012008——551——7
Large b-cell lymphoma diffuseD016403—C83.3431—17
Primary myelofibrosisD055728—D47.4—31—15
Endometrial neoplasmsD016889EFO_0004230——12—14
LiposarcomaD008080——111——2
Myeloproliferative disordersD009196—D47.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.095———12
LeukemiaD007938—C9563———7
LymphomaD008223—C85.942———6
NeoplasmsD009369—C8052———5
Myeloid leukemiaD007951—C9243———5
Colorectal neoplasmsD015179——22———3
Myelodysplastic syndromesD009190—D4612———3
CarcinomaD002277—C80.013———3
Non-small-cell lung carcinomaD002289——22———2
MelanomaD008545——11———2
Show 37 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509——3———14
Biphenotypic leukemia acuteD015456—C95.03————3
B-cell lymphomaD016393——2————2
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.02————2
Hematologic neoplasmsD019337——2————2
Non-hodgkin lymphomaD008228—C85.92————2
AggressionD000374EFO_0003015—1————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1————1
Alveolar soft part sarcomaD018234——1————1
Ewing sarcomaD012512EFO_0000173—1————1
Show 12 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MothersD009035——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSelinexor
INNselinexor
Description
Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.
Classification
Small molecule
Drug classexportin 1 inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1
Identifiers
PDB—
CAS-ID1393477-72-9
RxCUI—
ChEMBL IDCHEMBL3545185
ChEBI ID—
PubChem CID71481097
DrugBankDB11942
UNII ID31TZ62FO8F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
XPO1
XPO1
Organism
Homo sapiens
Gene name
XPO1
Gene synonyms
CRM1
NCBI Gene ID
7514
Protein name
exportin-1
Protein synonyms
chromosome region maintenance 1 homolog, Chromosome region maintenance 1 protein homolog, exportin 1 (CRM1 homolog, yeast), exportin-1 (required for chromosome region maintenance)
Uniprot ID
Q99433
Mouse ortholog
Xpo1 (103573)
exportin-1 (Q6P5F9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,685 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,512 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use